<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988544</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL16_0267</org_study_id>
    <nct_id>NCT02988544</nct_id>
  </id_info>
  <brief_title>Artificial Shrinkage of Fresh Blastocysts</brief_title>
  <acronym>BlastoCollapse</acronym>
  <official_title>Artificial Shrinkage of Fresh Blastocyst: Impact on Success Rates in Assisted Reproductive Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine if collapsing an embryo (or making it fold compactly by&#xD;
      taking away its fluid) before the transfer in the uterine cavity improves pregnancy rates in&#xD;
      assisted reproductive technology (ART).&#xD;
&#xD;
      Women coming to our ART center will be randomized in two groups : the collapsing group and a&#xD;
      control group.&#xD;
&#xD;
      Pregnancy rates will be compared in the two groups. A biomarker (cell free DNA) will also be&#xD;
      determined in each group and correlated to pregnancy occurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized study designed to determine if artificial shrinkage (AS)&#xD;
      before transfer of embryos impact clinical pregnancy rate in single blastocyst embryo&#xD;
      transfer (SBET) cycle. Women elected for SBET will be randomized on transfer day in two&#xD;
      arms:the AS group where blastocoelic cavity is artificially reduced by a laser pulse prior to&#xD;
      transfer and a control group.&#xD;
&#xD;
      Clinical pregnancy rates will be compared. Secondarily, rate of monozygotic twin pregnancy&#xD;
      and cell free DNA concentration in culture medium will be evaluated in the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 20, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Actual">August 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate embryo transfer</measure>
    <time_frame>5 weeks</time_frame>
    <description>Clinical pregnancy rate by transfer evaluate by the visualization of at least one gestational sac with fetal heart activity during pelvic ultrasound confirmed by a positive result of the quantitative Î²HCG blood test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Twin pregnancy rate by transfer</measure>
    <time_frame>5 weeks</time_frame>
    <description>Twin pregnancy rate by transfer evaluate the presence of 2 cardiac activities on ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free DNA level</measure>
    <time_frame>Baseline</time_frame>
    <description>Free DNA content contained in the drop of culture medium collected after transfer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Infertility Assisted Reproductive Technology</condition>
  <arm_group>
    <arm_group_label>Artificial shrinkage (AS) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Artificial shrinkage group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention on blastocoelic</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Artificial shrinkage</intervention_name>
    <description>Artificial shrinkage of blastocyst</description>
    <arm_group_label>Artificial shrinkage (AS) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Couple eligible for a transfer of a single embryo at the blastocyst stage&#xD;
&#xD;
          -  Available couple for a follow up of 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Attempt with frozen embryo or frozen oocyte&#xD;
&#xD;
          -  Attempt with a pre-implantation diagnosis&#xD;
&#xD;
          -  Patient has not signed informed consent&#xD;
&#xD;
          -  Couple in a period of exclusion determined by a previous study&#xD;
&#xD;
          -  Couple under legal protection, guardianship or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna AG GALA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single blastocyst embryo transfer</keyword>
  <keyword>Artificial Shrinkage</keyword>
  <keyword>Clinical pregnancy rate</keyword>
  <keyword>Cell free</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

